Other Events ·
Court rules U.S. Patent No. 11,826,327 valid and infringed by United Therapeutics
LQDALiquidia Corp
Liquidia Corporation reported a partial adverse ruling in Hatch-Waxman litigation filed by United Therapeutics Corporation regarding U.S. Patent No. 11,826,327 and its lead product YUTREPIA (treprostinil). The court found claims 1 and 14 valid and infringed, covering the treatment of pulmonary hypertension with interstitial lung disease (PH-ILD), while other asserted claims were deemed invalid. Liquidia intends to appeal and plans to submit a New Drug Application supplement to remove the PH-ILD indication from YUTREPIA's label. United Therapeutics has requested injunctive relief that could restrict product availability, though financial exposure remains unestimable due to ongoing proceedings. This company operates in the biopharmaceutical industry, developing therapies for respiratory and vascular diseases using proprietary PRINT technology.